Docs Who Lift Microdosing GLP-1 and Cagrisema headlines
Dec 23, 2024
Delve into the intriguing concepts of microdosing GLP-1 receptor agonists and the latest results from a new weight loss drug. Discover the balance between ethical medication access and corporate practices in healthcare. Hear about the eccentric quest for longevity and the disparities in medication availability. Explore the implications of microdosing terzepatide on inflammation versus weight loss. Unpack the ethical concerns surrounding cosmetic weight loss medications and the importance of responsible pharmaceutical practices.
AI Snips
Chapters
Transcript
Episode notes
Microdosing Semaglutide Ineffective
- Microdosing semaglutide (0.1 mg) showed no significant weight loss benefit compared to placebo in a diabetes trial.
- Higher doses (0.4 mg and above) demonstrated comparable or better results than liraglutide.
Therapeutic Microdosing Example
- A patient with type 1 diabetes achieved significant weight loss (14%) and insulin reduction on a moderate Wegovy dose (0.5 mg).
- This "therapeutic microdosing" highlights individual responses and potential benefits of lower doses.
Compounded Microdosing Risks
- Compounded microdosing lacks long-term safety and efficacy data, especially for cardiovascular benefits.
- Prioritize FDA-approved doses for established indications.